Hemas Pharmaceuticals has been appointed as the new official distributor for the complete range of OPPO Orthopedic rehabilitation products in Sri Lanka. 

OPPO, a US company with presence in Sri Lanka ,has beenthe market leader of the orthopedic rehabilitation product segment in Sri Lanka since its entry into the market in 2007.

Hemas will be the official distributor in the Sri Lankan Territory for OPPO, providing the strong presence and the widest reach needed in the market for a pharmaceutical product manufacturer. 

“OPPO is a proven market leader in orthopedic rehabilitation products, and Hemas, with its proven leadership in the industry, is best placed as the most trusted distributor in the country to take them to the next level in Sri Lanka .
We are excited about the synergies created by this partnership, which, in sync with our relationships with health care providers will enable us to serve patients to ensure the right fit for their needs from OPPO’s range of products.” said Jude Fernando, Managing Director, Hemas Pharmaceuticals and Hemas Surgicals & Diagnostics commenting on the partnership. The OPPO portfolio comes with over 81 categories and 473 different products, consisting of different lines in the Orthopedics and Rehabilitation Segment, Sports Medicine Segment, Prevention of injuries and Surgical segment. 

With a complete range of Orthopedic rehabilitation products, the partnership will focus on providing consumers with options to help prevent injuries and aid in the rehabilitation of athletes and others leading an active lifestyle.
Sam Chiang, VP Brand Development APAC , OPPO said, “Introducing innovative Orthopedic and rehabilitation products to relieve patient burden is a top priority for OPPO, and it is our delight to partner with Hemas Pharmaceuticals with decades of experience in working with healthcare professionals and patients to deliver the best solution. 

We are confident that the in-depth insights and hands-on knowledge of the Hemas Surgicals & Diagnostics team, coupled with the high standards of compliance they abide by, will bring OPPO closer to patients whilst retaining our industry-leading market position.”